Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01790243 · ClinicalTrials.gov registry record · NA
LEVANT 2 Safety Registry
A NA study, sponsored by C. R. Bard.
- Completed
- Registry status
- NA
- Development phase
- 1,189
- Enrollment target
NCT01790243: Completed NA study, sponsored by C. R. Bard.
NCT01790243 is a NA study that has completed, run by C. R. Bard. The registered enrollment target is 1,189 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (15% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01790243, a NA study, has completed, sponsored by C. R. Bard.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,189 participants
- Enrollment target
Study Summary
The primary objective of the LEVANT 2 Extended Follow-up Post-Approval Study (PAS 1) is to evaluate the long-term performance of the Lutonix Drug Coated Balloon (DCB) versus Percutaneous Transluminal Balloon Angioplasty (PTA) in the treatment of stenosis or occlusion of the femoropopliteal arteries.
Interventions
- DEVICE Lutonix Drug Coated Balloon
- DEVICE Standard PTA Balloon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,189 participants |
| Start Date | 2011-07-20 |
| Est. Completion | 2018-11-01 |
| Phase | NA |
What the finished NCT01790243 record still lists
NCT01790243 is an interventional study that assigns participants to a tested intervention. Its 1,189 participants enrollment target places it among the larger protocols in the corpus, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (15% lower).
The record links to 0 conditions, and to 2 interventions - of which Lutonix Drug Coated Balloon is the first listed.
NCT01790243 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01790243 about?
NCT01790243 is a clinical study titled "LEVANT 2 Safety Registry". The primary objective of the LEVANT 2 Extended Follow-up Post-Approval Study (PAS 1) is to evaluate the long-term performance of the Lutonix Drug Coated Balloon (DCB) versus Percutaneous Transluminal Balloon Angioplasty (PTA) in the treatment of stenosis or occlusion of the femoropopliteal arteries.
What is the current status of trial NCT01790243?
This trial is currently completed. It is a NA study. The enrollment target is 1,189 participants. The study started on 2011-07-20. Estimated completion is 2018-11-01.
What interventions are being tested in trial NCT01790243?
The interventions under investigation include: Lutonix Drug Coated Balloon (DEVICE), Standard PTA Balloon (DEVICE).
Who is sponsoring clinical trial NCT01790243?
This trial is sponsored by C. R. Bard, which has 75 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01790243's enrollment target sits among peer trials
1,189 89th of 2000 higher than 1,912 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05580419 · 1,188 participants · NA
Impact of 4PCP on Practitioner and Patient Outcomes
- NCT06290869 · 1,188 participants · Phase 3
Tobacco Education and Lung Health Study (TEAL)
- NCT04293562 · 1,186 participants · Phase 3
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- NCT07177339 · 1,196 participants · Phase 3
eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI